SEARCH

SEARCH BY CITATION

References

  • 1
    De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004; 101: 1046410469.
  • 2
    Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279: 2627426279.
  • 3
    Szokodi I, Tavi P, Földes G, Voutilainen-Myllylä S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91: 434440.
  • 4
    Horiuchi Y, Fujii T, Kamimura Y, Kawashima K. The endogenous, immunologically active peptide apelin inhibits lymphocytic cholinergic activity during immunological responses. J Neuroimmunol 2003; 144: 4652.
  • 5
    Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471476.
  • 6
    Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, et al. TNF-α up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006; 20: 15281530.
  • 7
    Scott IC, Masri B, D'Amico LA, Jin SW, Jungblut B, Wehman AM, et al. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell 2007; 12: 403413.
  • 8
    Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538: 162171.
  • 9
    Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275: 2106121067.
  • 10
    Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y. Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun 2002; 290: 539545.
  • 11
    Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 2004; 18: 19091911.
  • 12
    Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110( Suppl 1): II187II193.
  • 13
    Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 2006; 296: 177189.
  • 14
    Arroyo V, Ginès P, Jiménez W, Rodès J. Renal dysfunction in cirrhosis. In: Bircher J, Benhamou JP, Mc Intyre N, Rizzetto M, Rodés J, eds. Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford, UK: Oxford Medical Publications; 1999: 733761.
  • 15
    Morales-Ruiz M, Jimenez W. Nitric oxide and systemic and renal hemodynamic disturbances in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis Diagnosis and Treatment. 2nd ed. Malden, MA: Blackwell Publishing Ltd; 2005: 105114.
  • 16
    Jiménez W. Endocannabinoids and liver disease. HEPATOLOGY 2005; 41: 983985.
  • 17
    Clària J, Jimenez W. Experimental models of cirrhosis and ascites. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis Diagnosis and Treatment. 2nd ed. Malden, MA: Blackwell Publishing Ltd; 2005: 215226.
  • 18
    Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146: 231236.
  • 19
    Fernández-Varo G, Ros J, Morales-Ruiz M, Cejudo-Martín P, Arroyo V, Solé M, et al. Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol 2003; 162: 19851993.
  • 20
    Ros J, Fernández-Varo G, Muñoz-Luque J, Arroyo V, Rodés J, Gunnet JW, et al. Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br J Pharmacol 2005; 146: 654661.
  • 21
    Tugues S, Fernández-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis and portal pressure in cirrhotic rats. HEPATOLOGY 2007; 46: 19191926.
  • 22
    Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125172.
  • 23
    Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism. Regul Pept 2001; 99: 8792.
  • 24
    Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T. et al. Spatial and temporal role of the apelin/APJ system in the calibre size regulation of blood vessels during angiogenesis. EMBO J 2008; 27: 522534.
  • 25
    Ronkainen VP, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, et al. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 2007; 21: 18211830.